NAD + supplementation reduces neuroinflammation and cell senescence in a transgenic mouse model of Alzheimer's disease via cGAS-STING.
Level 5 - mechanism / opinion, no new human data
Animal model and in vitro laboratory study without human clinical trial data
PubMed 34497121 · doi:10.1073/pnas.2011226118
What was done
Researchers administered the NAD+ precursor nicotinamide riboside (NR) for 5 months to APP/PS1 transgenic Alzheimer's disease (AD) model mice. They assessed brain NAD+ levels, neuroinflammatory markers, microglial and astrocyte activation, NLRP3 inflammasome expression, DNA damage, apoptosis, cellular senescence, ectopic cytoplasmic DNA, and cGAS-STING pathway activation. They also conducted in vitro experiments using microglia and human AD fibroblasts and evaluated synaptic and cognitive functions in the mice.
What was found
The abstract reports no exact numerical figures or effect sizes. Qualitatively, 5 months of NR treatment in APP/PS1 mice increased brain NAD+ levels, reduced proinflammatory cytokine expression, and decreased microglial and astrocyte activation. NR reduced NLRP3 inflammasome expression, DNA damage, apoptosis, cellular senescence, and ectopic cytoplasmic DNA, while normalizing elevated cGAS-STING signaling, inducing mitophagy, and improving synaptic and cognitive performance.
Why it matters
This study links NAD+ depletion to cGAS-STING pathway-driven neuroinflammation and senescence in an AD model, indicating a potential mechanistic target for addressing neurodegeneration.
Limits
The findings are derived entirely from transgenic animal models and in vitro cell cultures, limiting direct clinical applicability to human Alzheimer's disease. The abstract provides no sample sizes (n), dosing metrics, quantitative effect estimates, or variance measures.
Cited by
- supports Boosting NAD levels in the brain improves memory and slows Alzheimer's disease progression in mouse models.